Search for serendipitous TNO occultation in X-rays

To study the population properties of small, remote objects beyond Neptune's orbit in the outer solar system, of kilometer size or smaller, serendipitous occultation search is so far the only way. For hectometer-sized Trans-Neptunian Objects (TNOs), optical shadows actually disappear because of diffraction. Observations at shorter wave lengths are needed. Here we report the effort of TNO occultation search in X-rays using RXTE/PCA data of Sco X-1 taken from June 2007 to October 2011. No definite TNO occultation events were found in the 334 ks data. We investigate the detection efficiency dependence on the TNO size to better define the sensible size range of our approach and suggest upper limits to the TNO size distribution in the size range from 30 m to 300 m. A list of X-ray sources suitable for future larger facilities to observe is proposed.Comment: Accepted to publish in MNRA

Color-complexity enabled exhaustive color-dots identification and spatial patterns testing in images

Targeted color-dots with varying shapes and sizes in images are first exhaustively identified, and then their multiscale 2D geometric patterns are extracted for testing spatial uniformness in a progressive fashion. Based on color theory in physics, we develop a new color-identification algorithm relying on highly associative relations among the three color-coordinates: RGB or HSV. Such high associations critically imply low color-complexity of a color image, and renders potentials of exhaustive identification of targeted color-dots of all shapes and sizes. Via heterogeneous shaded regions and lighting conditions, our algorithm is shown being robust, practical and efficient comparing with the popular Contour and OpenCV approaches. Upon all identified color-pixels, we form color-dots as individually connected networks with shapes and sizes. We construct minimum spanning trees (MST) as spatial geometries of dot-collectives of various size-scales. Given a size-scale, the distribution of distances between immediate neighbors in the observed MST is extracted, so do many simulated MSTs under the spatial uniformness assumption. We devise a new algorithm for testing 2D spatial uniformness based on a Hierarchical clustering tree upon all involving MSTs. Our developments are illustrated on images obtained by mimicking chemical spraying via drone in Precision Agriculture.Comment: 21 pages, 21 figure

Millisecond dips in the 2007-2009 RXTE/PCA lightcurve of Sco X-1 and one possible occultation event

Serendipitous stellar occultation search is so far the only way to detect the existence of very small, very dim, remote objects in the solar system. To date, however, there are only very few reported detections for trans-Neptunian objects (TNOs) in optical bands. In the X-ray band, with the RXTE/PCA data of Sco X-1 taken from June 2007 to October 2009, we found one possible X-ray occultation event. We discuss the veracity and properties of this event, and suggest upper limits to the size distribution of TNOs at hectometer size and of Main-Belt Asteroids (MBAs) at decameter size.Comment: 8 pages, 5 figures, to appear in MNRAS (accepted on Sep. 10, 2010

Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

BackgroundThe use of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA) has long been considered the standard regimen for preventing chemotherapy-induced nausea and vomiting (CINV) prior to hematopoietic stem cell transplantation (HSCT). However, their therapeutic outcomes have been unsatisfactory. NEPA, an oral formulation combining the neurokinin-1 receptor antagonist netupitant and the 5HT3RA palonosetron, has received regulatory approval for the management of highly and moderately emetogenic chemotherapy. This study aims to compare the efficacy of NEPA with that of 5HT3RA alone in preventing CINV among patients undergoing multiday conditioning chemotherapy prior to HSCT.Patients and methodsWe conducted a retrospective analysis of patients who underwent HSCT between September 2019 and September 2022. Efficacy outcomes were assessed based on the rates of patients achieving complete response (CR: no emesis and no use of rescue medication), complete control (CC: CR without significant nausea), no vomiting, and no significant nausea.ResultsThe NEPA group consisted of 106 patients, while the 5HT3RA group included 107 patients. The NEPA group exhibited significantly higher rates of CR compared to the 5HT3RA group during the overall phase (71.7% vs. 32.7%, P<0.001), acute phase (78.3% vs. 43.0%, P<0.001), and delayed phase (84.9% vs. 58.9%, P<0.001). Similarly, rates of CC, no vomiting, and no significant nausea were significantly better in the NEPA group across all phases (P<0.001).ConclusionNEPA demonstrated superior efficacy compared to 5HT3RA in preventing CINV during all phases of multiday conditioning regimens among patients undergoing HSCT

Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients

BACKGROUND: In the general population, metabolic syndrome (MetS) is correlated with visceral fat and a risk factor for cardiovascular disease (CVD); however, little is known about the significance of abdominal fat and its association with inflammation and medication use in peritoneal dialysis (PD) patients. We investigated the relationship of visceral fat area (VFA) with C-reactive protein (CRP) levels and medication use in PD patients and followed their clinical outcomes. METHODS: In a prospective study from February 2009 to February 2012, we assessed diabetes mellitus (DM) status, clinical and PD-associated characteristics, medication use, CRP levels, components of MetS, and VFA in 183 PD patients. These patients were categorized into 3 groups based on MetS and DM status: non-MetS (group 1, n = 73), MetS (group 2, n = 65), and DM (group 3, n = 45). VFA was evaluated by computed tomography (CT) and corrected for body mass index (BMI). RESULTS: Patients in group 1 had smaller VFAs than patients in groups 2 and 3 (3.2 ± 1.8, 4.6 ± 1.9, and 4.9 ± 2.0 cm(2)/[kg/m(2)], respectively, P < 0.05) and lower CRP levels (0.97 ± 2.31, 1.27 ± 2.57, and 1.11 ± 1.35 mg/dL, respectively, P < 0.05). VFA increased with the number of criteria met for MetS. After adjusting for age, body weight, and sex, CRP and albumin levels functioned as independent positive predictors of VFA; on other hand, the use of renin-angiotensin system blockers was inversely correlated with VFA in PD patients without DM. In the survival analysis, DM patients (group 3) had the poorest survival among the 3 groups, but no significant differences were found between groups 1 and 2. CONCLUSION: This study showed that VFA and MetS are associated with CRP levels but cannot predict survival in PD patients without DM. The complex relationship of nutritional parameters to VFA and MetS may explain these results. The type of antihypertensive medication used was also associated with the VFA. The mechanisms behind these findings warrant further investigation

miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions

MicroRNAs (miRNAs) are small non-coding RNA molecules capable of negatively regulating gene expression to control many cellular mechanisms. The miRTarBase database (http://mirtarbase.mbc.nctu.edu.tw/) provides the most current and comprehensive information of experimentally validated miRNA-target interactions. The database was launched in 2010 with data sources for >100 published studies in the identification of miRNA targets, molecular networks of miRNA targets and systems biology, and the current release (2013, version 4) includes significant expansions and enhancements over the initial release (2010, version 1). This article reports the current status of and recent improvements to the database, including (i) a 14-fold increase to miRNA-target interaction entries, (ii) a miRNA-target network, (iii) expression profile of miRNA and its target gene, (iv) miRNA target-associated diseases and (v) additional utilities including an upgrade reminder and an error reporting/user feedback system